Cargando…

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany

The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dabisch, Inna, Dethling, Jürgen, Dintsios, Charalabos-Markos, Drechsler, Melanie, Kalanovic, Daniel, Kaskel, Peter, Langer, Frank, Ruof, Jörg, Ruppert, Thorsten, Wirth, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901346/ https://www.ncbi.nlm.nih.gov/pubmed/24460706 http://dx.doi.org/10.1186/2191-1991-4-2

Ejemplares similares

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015)

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013)

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?
por: Ruof, Jörg, et al.
Publicado: (2016)

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021)

“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases
por: Staab, Thomas, et al.
Publicado: (2016)

Relevance of Variations in the Opposing Dentition for the Functionality of Fixed and Removable Partial Dentures: A Systematic Review
por: Pommer, Bernhard, et al.
Publicado: (2012)

The impact of HTA reports on health policy: a systematic review
por: Gerhardus, Ansgar, et al.
Publicado: (2005)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

Coated stents to prevent restenosis in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2005)

Quantified patient preferences for lifestyle intervention programs for diabetes prevention—a protocol for a systematic review
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2018)

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Intravascular brachytherapy for peripheral vascular disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Laparoscopic vs. open appendectomy: systematic review of medical efficacy and health economic analysis
por: Gorenoi, Vitali, et al.
Publicado: (2007)

Promoting physical activity in low back pain patients: six months follow-up of a randomised controlled trial comparing a multicomponent intervention with a low intensity intervention
por: Schaller, Andrea, et al.
Publicado: (2016)

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
por: Dintsios, C. M., et al.
Publicado: (2020)

External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement—a protocol for a systematic review
por: Ogurtsova, Katherine, et al.
Publicado: (2017)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Implementation of a multicomponent intervention to prevent physical restraints in nursing home residents (IMPRINT): study protocol for a cluster-randomised controlled trial
por: Abraham, Jens, et al.
Publicado: (2015)

Analysis of composite endpoints in gene expression studies in oncology
por: Marhoon, ZA, et al.
Publicado: (2015)

Endpoint surrogacy in oncology Phase 3 randomised controlled trials
por: Zhang, Jianrong, et al.
Publicado: (2020)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

Remuneration for non-interventional studies – results of a survey in the pharmaceutical industry in Germany
por: Ruppert, Thorsten, et al.
Publicado: (2012)

In‐hospital worsening heart failure: a clinically relevant endpoint?
por: Clark, Andrew L., et al.
Publicado: (2017)

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology
por: Serpas, Victoria J., et al.
Publicado: (2018)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Challenges in translating endpoints from trials to observational cohort studies in oncology
por: Ording, Anne Gulbech, et al.
Publicado: (2016)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Why do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany
por: Walach, Harald, et al.
Publicado: (2022)

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
por: Chabner, Bruce A.
Publicado: (2017)

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
por: Kemp, Robert, et al.
Publicado: (2017)

Research Question, Objectives, and Endpoints in Clinical and Oncological Research: A Comprehensive Review
por: Purna singh, Addanki, et al.
Publicado: (2022)

A conscious mouse model of gastric ileus using clinically relevant endpoints
por: Firpo, Matthew A, et al.
Publicado: (2005)

Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats
por: Sufka, Kenneth J., et al.
Publicado: (2016)

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
por: Ang, Joo Ern, et al.
Publicado: (2012)

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making
por: Schlegl, Evelyn, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ns475bb09a8u23lleekk328msa